NEW YORK (GenomeWeb) – Greenwood Genetic Center announced today that it has signed an agreement to use FDNA's Face2Gene next-generation phenotyping technology in order to gain insights into thousands of undiagnosed patients with rare diseases.
Face2Gene uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses based on a database of more than 10,000 rare disease syndromes.
Under the terms of the deal, GGC will use Face2Gene to analyze nearly 80,000 undiagnosed cases with the goal of generating actionable answers for these patients, identifying new syndrome-related clinical phenotypes, and making rare disease discoveries that can advance overall research. FDNA will use data from these analyses to strengthen its database of known diagnoses.
Additional terms were not disclosed.
"The GGC clinical team has already received the first insights from FDNA," Hannah Warren, a clinical genetic counselor at GGC, said in a statement. "There are dozens of high priority, undiagnosed cases that have been flagged by Face2Gene due to their statistically significant facial analysis insights. These new insights may help find a diagnosis for patients who have been searching for answers for much too long."